Celsion Corp.
10220-L Old Columbia Road
Columbia,
MD 21046-2364
United States - Map
Phone: 410-290-5390
Fax: 410-290-5394
Web Site: http://www.celsion.com
| Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. Its lead product includes ThermoDox, an oncology drug, which is a heat activated liposomal encapsulation of doxorubicin is in Phase III clinical trials for primary liver cancer and Phase II study for recurrent chest wall breast cancer. The company has a licensing agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market; and a licensing agreement with Duke University to patent Dukes thermo-liposome technology in the United States, and to future patents received by Duke in Canada, Europe, Japan, and Australia. It has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with Celsion's heat activated liposomal technology to develop new cancer drugs. Celsion Corporation was founded in 1982 and is based in Columbia, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael H. Tardugno , 58
Chief Exec. Officer, Pres |
N/A
| N/A | Dr. Nicholas Borys M.D., 47
Chief Medical Officer and VP |
$
315.00K | N/A | Mr. Sean F. Moran MBA, 51
Chief Financial Officer, Sr. VP and Sec. |
N/A
| N/A | Ms. Anita J. Finkelstein , 52
VP and Gen. Counsel |
N/A
| N/A | Mr. Raj Prabhakar ,
Exec. Director of Strategic Planning & Bus. Devel. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
